autologous tumor-mRNA transfected dendritic cells

Autologous tumor-mRNA transfected dendritic cells are a highly personalized cellular immunotherapy prepared by collecting a patient’s own dendritic cells and transfecting them ex vivo with mRNA derived from that patient’s tumor tissue, usually via electroporation[1][3][4][6][7]. These dendritic cells, when re-administered to the patient, present a broad array of tumor antigens—encoding both shared and individualized epitopes—to the immune system, thus inducing cytotoxic T lymphocyte responses directed against the tumor[1][2][4][7]. The mechanism exploits the potent antigen-presenting capabilities of dendritic cells to stimulate robust T-cell–mediated antitumor immunity; mRNA transfection enables presentation of multiple, patient-specific antigens, overcoming limitations of MHC restriction observed with peptide vaccines[1][2][4][7]. This approach has been evaluated in phase I/II clinical trials primarily for advanced malignancies such as melanoma[1][3][6], prostate cancer[2], leukemias, glioblastoma, renal cell carcinoma, pancreatic cancer, and others[4]. Key developers and clinical investigators include academic centers and hospitals; specific proprietary products and corporate developers are not consistently defined for this individualized therapy.

Other names

autologous mRNA-transfected dendritic cellsautologous dendritic cell vaccineautologous DC vaccinemRNA-electroporated dendritic cells